Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2025-04-08 | Timothy P. Walbert joined our Board in February 2025. Mr. Walbert is currently senior advisor at Amgen. He previously served as chairman, president and CEO of Horizon Therapeutics. Mr. Walbert received a pro-rated new director grant valued at $200,000 on February 24, 2025 but is not shown in the 2024 compensation table. |
| Filing Date | Source Excerpt |
|---|---|
| 2011-04-20 | Timothy P. Walbert has been a director since November of 2010. ... The Compensation Committee, currently consisting of Messrs. Bowes, Van Ness, Walbert and Wyszomierski... The Nominating & Governance Committee, currently consisting of Messrs. Bowes (Chairman), Hutt, Van Ness and Walbert. |
| 2012-04-11 | Timothy P. Walbert has been a director since November of 2010. ... The Compensation Committee, currently consisting of Messrs. Bowes (Chairman), Van Ness, Walbert and Wyszomierski ... The Nominating & Governance Committee, currently consisting of Messrs. Bowes (Chairman), Hutt, Van Ness and Walbert ... The table below sets forth the 2011 compensation for members of the Board who were non-employee directors at any time during 2011. ... Timothy P. Walbert total compensation $115,493. |
| 2013-04-11 | Timothy P. Walbert has been a director since November of 2010. |
| 2014-04-11 | Timothy P. Walbert has been a director since November of 2010. Mr. Walbert is Chairman, President and Chief Executive Officer of Horizon Pharma. |
| 2015-04-10 | Timothy P. Walbert has been a director since November of 2010. Mr. Walbert is Chairman, President and Chief Executive Officer of Horizon Pharma. |
| 2016-04-08 | Timothy P. Walbert has been a director since November of 2010. Mr. Walbert has served as president and chief executive officer since June 2008, and as chairman since March 2010, of Horizon Pharma plc, a publicly traded biopharmaceutical company focused on orphan, primary care and specialty medicines. |
| 2016-09-12 | Timothy P. Walbert is listed as a director with beneficial ownership in the proxy statement on pages 13-14. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22